field
clinic
microbiolog
compris
diagnost
microbiolog
identif
pathogen
clinic
sampl
guid
manag
treatment
strategi
patient
infect
public
health
microbiolog
surveil
monitor
infecti
diseas
outbreak
commun
tradit
diagnost
techniqu
microbiolog
laboratori
includ
growth
isol
microorgan
cultur
detect
pathogenspecif
antibodi
serolog
antigen
molecular
identif
microbi
nucleic
acid
dna
rna
commonli
via
pcr
molecular
assay
target
limit
number
pathogen
use
specif
primer
probe
metagenom
approach
character
dna
rna
present
sampl
enabl
analysi
entir
microbiom
well
human
host
genom
transcriptom
patient
sampl
metagenom
approach
appli
decad
character
variou
nich
rang
marin
toxic
arthropod
diseas
human
tool
also
use
identifi
infect
ancient
discov
novel
viral
character
human
virom
healthi
diseas
forens
capac
detect
potenti
pathogen
bacteria
virus
fungi
parasit
sampl
simultan
interrog
host
respons
great
potenti
util
diagnosi
infecti
diseas
metagenom
clinic
applic
deriv
root
use
microarray
earli
earli
success
use
technolog
includ
discoveri
sar
gene
profil
mutat
indepth
microbiom
analysi
differ
site
human
howev
advent
nextgener
sequenc
ng
technolog
jumpstart
metagenom
first
time
million
billion
read
could
gener
singl
run
permit
analysi
entir
genet
content
clinic
environment
sampl
prolifer
avail
sequenc
instrument
exponenti
decreas
sequenc
cost
ensu
decad
drove
rapid
adopt
ng
technolog
date
sever
studi
provid
glimps
promis
ng
clinic
public
health
set
exampl
ng
use
clinic
diagnosi
neuroleptospirosi
critic
ill
boy
case
first
demonstr
util
metagenom
ng
mng
provid
clinic
action
inform
success
diagnosi
prompt
appropri
target
antibiot
treatment
eventu
recoveri
patient
exampl
public
health
microbiolog
includ
use
ng
combin
transmiss
network
investig
outbreak
escherichia
coli
strain
surveil
antimicrobi
resist
food
suppli
bacteri
wholegenom
increasingli
big
data
provid
mng
leverag
clinic
purpos
includ
character
antibiot
resist
directli
clinic
analysi
human
host
respons
transcriptom
data
predict
caus
infect
evalu
diseas
thu
mng
key
driver
precis
diagnosi
infecti
diseas
advanc
precis
medicin
effort
person
patient
care
field
despit
potenti
recent
success
metagenom
clinic
diagnost
applic
lag
behind
research
advanc
owe
number
factor
complex
interplay
microbi
host
factor
influenc
human
health
exemplifi
role
microbiom
modul
host
immun
often
unclear
whether
detect
microorgan
contamin
colon
bona
fide
pathogen
addit
univers
refer
standard
proven
approach
demonstr
test
valid
reproduc
qualiti
assur
clinic
metagenom
assay
lack
consider
cost
reimburs
turnaround
time
regulatori
consider
perhap
importantli
clinic
util
also
remain
major
hurdl
routin
implement
clinic
mng
patient
care
review
variou
applic
mng
current
exploit
clinic
public
health
set
discuss
challeng
involv
adopt
mng
clinic
laboratori
includ
valid
regulatori
consider
extend
beyond
initi
develop
research
laboratori
propos
step
overcom
challeng
final
envisag
futur
direct
field
clinic
metagenom
anticip
achiev
next
year
target
approach
benefit
increas
number
proport
pathogen
read
sequenc
data
step
increas
detect
sensit
microorgan
target
although
limit
breadth
potenti
pathogen
identifi
exampl
target
approach
use
highli
conserv
primer
univers
pcr
amplif
detect
microorgan
correspond
specif
type
clinic
sampl
ribosom
rna
rrna
gene
amplif
rrna
intern
transcrib
spacer
gene
amplif
fig
previous
approach
follow
sanger
sequenc
result
pcr
amplicon
identifi
pathogen
make
diagnosi
step
commonli
accomplish
use
ng
univers
pcr
detect
bacteria
fungi
adopt
mani
hospit
laboratori
increas
number
proport
infecti
although
techniqu
limit
breadth
detect
bacteria
fungi
even
limit
rang
target
mycobacteria
depend
primer
set
use
concern
regard
anoth
exampl
target
ng
approach
design
primer
tile
across
genom
facilit
pcr
amplif
amplicon
ng
recoveri
viral
genom
directli
clinic
method
use
track
evolut
spread
zika
viru
zikv
ebola
viru
west
demonstr
realtim
monitor
impact
public
health
intervent
anoth
target
approach
captur
probe
enrich
wherebi
metagenom
librari
subject
hybrid
use
captur
bait
probe
gener
bp
length
number
probe
vari
less
although
enrich
method
shown
increas
sensit
metagenom
detect
research
set
especi
virus
yet
use
routin
clinic
diagnosi
promis
applic
approach
may
enrich
clinic
sampl
character
antibiot
consider
problem
hospit
primari
focu
us
nation
action
plan
combat
antibioticresist
howev
drawback
captur
probe
enrich
compar
untarget
approach
infecti
diseas
diagnosi
includ
bia
toward
target
microorgan
ad
step
increas
cost
long
hybrid
time
hour
result
addit
process
need
maxim
effici
untarget
shotgun
mng
analys
forego
use
specif
primer
instead
entireti
dna
andor
rna
revers
transcript
cdna
sequenc
pure
cultur
bacteria
fungi
mng
read
assembl
partial
complet
genom
genom
sequenc
use
subtyp
andor
monitor
hospit
outbreak
support
infect
control
andor
public
health
surveil
effort
exampl
semin
studi
describ
use
wholegenom
sequenc
multidrugresist
carbapenemaseproduc
klebsiella
pneumonia
track
origin
evolut
hospit
studi
demonstr
first
time
highresolut
map
like
transmiss
event
hospit
unexpect
basi
initi
epidemiolog
data
also
identifi
put
resist
mutat
emerg
resist
strain
integr
genom
epidemiolog
data
yield
action
insight
would
use
curb
transmiss
untarget
mng
clinic
sampl
perhap
promis
approach
comprehens
diagnosi
infect
principl
nearli
pathogen
includ
virus
bacteria
fungi
parasit
identifi
singl
mng
needleinahaystack
endeavour
small
proport
typic
read
nonhuman
subset
may
correspond
potenti
pathogen
limit
mng
sensit
approach
critic
depend
level
background
tissu
exampl
increas
human
host
background
rel
cellfre
bodi
fluid
result
reduc
number
proport
microbi
read
henc
decreas
mng
moreov
defin
specif
microbi
profil
diagnost
predict
diseas
develop
difficult
especi
nonsteril
site
harbour
complex
microbiom
respiratori
secret
nevertheless
sever
group
success
valid
mng
clinic
laboratori
improv
amend
clia
certifi
clinic
laboratori
diagnosi
infect
includ
mening
assay
avail
clinic
refer
test
patient
mani
research
use
mng
instead
target
sequenc
rrna
gene
indepth
character
grow
public
awar
microbiom
like
involv
acut
chronic
diseas
howev
microbiomebas
test
clinic
valid
diagnosi
treatment
diseas
part
owe
incomplet
understand
complex
microbiom
role
diseas
pathogenesi
one
futur
clinic
applic
microbiom
analysi
may
manag
treatment
clostridium
difficileassoci
diseas
c
difficil
opportunist
bacterium
infect
gut
result
product
toxin
caus
diarrhoea
dehydr
sepsi
death
c
difficil
infect
occur
set
microbiom
alter
factor
exposur
broadspectrum
antibiot
recent
gastrointestin
import
microbiom
c
difficil
infect
underscor
effect
faecal
stool
transplant
treat
potenti
cure
use
mng
character
microbiom
multipl
studi
facilit
develop
bacteri
probiot
mixtur
administ
pill
prophylaxi
treatment
c
difficileassoci
diseas
fig
anoth
potenti
applic
microbiom
analysi
bacteri
divers
provid
clue
whether
patient
ill
infecti
noninfecti
exampl
studi
mng
identif
respiratori
pathogen
patient
pneumonia
found
individu
cultureproven
infect
significantli
less
divers
respiratori
alter
microbiom
known
dysbiosi
also
shown
relat
obes
diabet
mellitu
inflammatori
bowel
manipul
microbiom
may
pathway
treat
patholog
condit
clinic
mng
typic
focus
microbi
read
howev
complementari
role
analysi
gene
express
studi
human
host
respons
fig
mng
rna
librari
use
detect
pathogen
rna
virus
clinic
sampl
incident
produc
host
gene
express
data
transcriptom
rnaseq
although
rnaseq
analys
commonli
perform
whole
blood
peripher
blood
mononuclear
cell
pbmc
sampl
bodi
fluid
tissu
type
potenti
amen
analys
classif
gene
express
profil
use
rnaseq
use
character
sever
infect
includ
staphylococc
lyme
tuberculosi
discrimin
latent
activ
diseas
risk
machinelearningbas
analys
rnaseq
data
use
cancer
translat
approach
may
promis
infecti
diseas
panel
contain
limit
number
host
biomark
develop
diagnost
assay
bacteri
although
rnaseqbas
assay
clinic
valid
date
use
patient
potenti
clinic
impact
rnaseq
analys
high
interrog
rna
read
microorgan
correspond
activ
microbi
gene
express
might
enabl
discrimin
infect
versu
live
viabl
versu
dead
moreov
rnaseq
analys
human
host
use
identifi
novel
underappreci
interact
directli
clinic
sampl
previous
shown
patient
lyme
rnaseq
may
particularli
use
clinic
case
caus
pathogen
transient
present
earli
lyme
arbovir
infect
includ
west
nile
analog
serolog
test
indirect
diagnosi
infect
may
possibl
basi
pathogenspecif
human
host
respons
analysi
pathogenspecif
host
respons
may
also
use
discrimin
bona
fide
caus
pathogen
pathogen
complex
clinic
metagenom
sampl
polymicrobi
abscess
respiratori
yet
anoth
promis
applic
rnaseq
discrimin
infecti
versu
noninfecti
caus
acut
ill
judg
like
noninfecti
exampl
autoimmun
diseas
basi
host
respons
exampl
clinician
may
will
discontinu
antibiot
treat
patient
aggress
steroid
immunosuppress
medic
largescal
sequenc
data
continu
gener
perhap
driven
routin
clinic
mng
test
secondari
mine
human
read
might
improv
accuraci
clinic
diagnos
incorpor
microbi
host
gene
express
data
oncolog
wholegenom
direct
ng
approach
identifi
mutat
gene
use
simultan
uncov
virus
associ
cancer
herpesvirus
papillomavirus
polyomavirus
andor
gather
data
exampl
mng
critic
discoveri
merkel
cell
polyomaviru
fig
believ
caus
merkel
cell
carcinoma
rare
skin
cancer
seen
commonli
elderli
date
us
food
drug
administr
fda
approv
clinic
use
two
ng
panel
test
action
genom
aberr
tumour
detect
read
correspond
integr
exogen
virus
sampl
would
possibl
addit
specif
viral
probe
panel
accomplish
incident
sequenc
whole
tumour
genom
exom
addit
knowledg
integr
activ
viral
infect
cancer
involv
signal
pathway
may
inform
prevent
therapeut
intervent
target
antivir
andor
chemotherapeut
evidenc
decreas
risk
hepat
c
virusassoci
hepatocellular
carcinoma
treatment
directact
antivir
futur
mng
cellfre
dna
liquid
biopsi
sampl
exampl
plasma
might
leverag
simultan
identif
earli
cancer
diagnosi
infect
immunocompromis
patient
box
key
limit
mng
decreas
sensit
high
background
either
predominantli
human
host
exampl
tissu
biopsi
microbiom
exampl
stool
background
clinic
relev
pathogen
load
infect
shigella
flexneri
stool
patient
zikv
plasma
patient
vectorborn
febril
low
copi
per
ml
host
deplet
method
rna
librari
develop
shown
effect
includ
dnase
treatment
extract
remov
residu
human
background
use
rna
probe
follow
rnase
h
antibodi
human
mitochondri
rrna
abund
host
rna
type
clinic
sampl
andor
approach
deplet
abund
sequenc
unfortun
compar
effect
parallel
method
dna
librari
limit
enrich
time
rang
achiev
use
antibodi
methyl
human
host
enrich
microbi
read
owe
lack
methyl
dna
pathogen
genom
differenti
lysi
human
cell
follow
degrad
background
dna
dnase
thu
retain
enrich
nucleic
acid
organ
cell
wall
includ
bacteria
fungi
shown
provid
substanti
microbi
enrich
howev
perform
differenti
lysi
method
limit
number
factor
limit
includ
potenti
decreas
sensit
microorgan
without
cell
wall
mycoplasma
spp
parasit
possibl
paradox
increas
exogen
background
contamin
use
addit
inabl
detect
free
nucleic
acid
dead
organ
lyse
vivo
human
host
immun
cell
antibiot
treatment
import
retain
abil
cellfre
dna
detect
cultureneg
sampl
dead
organ
also
incorpor
propidium
monoazid
treatment
step
select
dna
live
organ
may
clinic
use
enrich
method
gener
differenti
lysi
propidium
monoazid
approach
would
also
cumbersom
implement
highli
reproduc
fashion
need
clinic
laboratori
valid
extent
human
host
background
limit
may
overcom
brute
forc
made
possibl
increas
capac
avail
sequenc
instanc
astroviru
detect
child
enceph
ultradeep
sequenc
brain
tissu
yield
read
million
yet
anoth
approach
improv
sensit
leverag
hybrid
method
enrich
metagenom
sequenc
spike
combin
target
untarget
sequenc
method
use
variabl
size
panel
short
primer
ad
spike
reaction
mixtur
enrich
specif
target
organ
retain
breadth
metagenom
sequenc
offtarget
organ
spike
revers
transcript
step
panel
zikvspecif
primer
found
increas
number
zikv
read
tenfold
without
appreci
decreas
broad
metagenom
sensit
pathogen
enabl
wholegenom
viral
sequenc
character
zikv
spread
brazil
central
america
complex
mng
analysi
requir
highli
train
personnel
extrem
care
sampl
handl
avoid
error
crosscontamin
even
miniscul
amount
exogen
dna
rna
introduc
sampl
collect
aliquot
nucleic
acid
extract
librari
prepar
pool
yield
detect
signal
contamin
read
addit
laboratori
surfac
consum
reagent
dna
free
databas
background
microorgan
commonli
detect
mng
data
aris
normal
flora
laboratori
typic
need
maintain
accur
mng
analys
microorgan
list
either
report
requir
higher
threshold
report
clinic
signific
organ
clinic
laboratori
oper
character
defin
workflow
schedul
staf
level
less
amen
ondemand
test
research
laboratori
sampl
typic
handl
batch
frequenc
batch
analysi
major
determin
overal
turnaround
time
unless
fulli
autom
samplehandl
system
readili
avail
wet
lab
manipul
mng
requir
consider
handson
time
perform
well
clinic
staff
highli
train
molecular
biolog
procedur
ergonom
concern
repetit
task
pipet
well
potenti
inadvert
sampl
mixup
omiss
critic
step
workflow
maintain
high
qualiti
complex
mng
procedur
stress
staff
slight
deviat
sampl
handl
lead
major
chang
result
gener
separ
assay
workflow
multipl
discret
step
perform
rotat
shift
help
avoid
laboratori
error
wellcharacter
refer
standard
control
need
ensur
mng
assay
qualiti
stabil
time
avail
metagenom
refer
materi
highli
custom
specif
applic
exampl
zymobiom
microbi
commun
standard
microbiom
analys
bacteri
fungal
andor
focus
limit
spectrum
organ
exampl
nation
institut
standard
technolog
nist
refer
materi
mix
microbi
dna
detect
contain
thu
materi
may
applic
untarget
mng
analys
custom
mixtur
consist
pool
microorgan
mock
microbi
commun
nucleic
acid
develop
extern
control
establish
limit
detect
mng
test
intern
spikein
control
standard
avail
ng
applic
transcriptom
analysi
rnaseq
extern
rna
control
consortium
ercc
rna
standard
compos
synthet
rna
oligonucleotid
span
rang
nucleotid
length
complet
set
portion
ercc
rna
standard
dna
equival
use
spikein
intern
control
control
assay
inhibit
quantifi
titr
detect
pathogen
standard
curv
nonetheless
lack
univers
accept
refer
standard
mng
make
difficult
compar
assay
perform
differ
laboratori
critic
need
standard
refer
organ
genom
materi
facilit
comparison
defin
optim
analysi
method
userfriendli
bioinformat
softwar
analysi
mng
data
current
avail
thu
custom
bioinformat
pipelin
analysi
clinic
mng
still
requir
highli
train
program
staff
develop
valid
maintain
pipelin
clinic
use
laboratori
either
host
comput
server
local
move
bioinformat
analysi
data
storag
cloud
platform
either
case
hardwar
softwar
setup
complex
adequ
measur
must
place
protect
confidenti
patient
sequenc
data
inform
especi
cloud
environ
storag
requir
sequenc
data
quickli
becom
quit
larg
clinic
laboratori
must
decid
quantiti
locat
durat
data
storag
bioinformat
pipelin
mng
analysi
use
number
differ
algorithm
usual
develop
research
set
constantli
updat
softwar
develop
wet
lab
procedur
usual
necessari
make
custom
modif
pipelin
softwar
lock
softwar
refer
databas
purpos
clinic
typic
bioinformat
pipelin
consist
seri
analysi
step
raw
input
fastq
file
includ
qualiti
lowcomplex
filter
adaptor
trim
human
host
subtract
microorgan
identif
align
refer
databas
option
sequenc
assembl
taxonom
classif
individu
read
andor
contigu
sequenc
contig
level
famili
genu
speci
fig
step
pipelin
must
care
assess
accuraci
complet
data
process
consider
propag
error
sensit
analys
perform
inclus
silico
data
data
gener
clinic
sampl
custom
data
set
prepar
mimic
input
sequenc
data
expand
rang
microorgan
detect
silico
use
standard
refer
materi
ng
data
set
also
help
compar
evalu
differ
bioinformat
addit
public
databas
microbi
refer
genom
continu
updat
laboratori
need
keep
track
exact
version
use
addit
deal
potenti
misannot
databas
error
larger
complet
databas
contain
publicli
deposit
sequenc
nation
center
biotechnolog
inform
ncbi
nucleotid
databas
comprehens
also
contain
error
curat
limit
databas
fda
refer
viral
databas
rvdb
combin
approach
incorpor
annot
sequenc
multipl
databas
may
enabl
greater
confid
sensit
specif
microorgan
identif
perform
valid
verif
bioinformat
analysi
constitut
timeconsum
endeavour
includ
analysi
control
patient
data
set
comparison
orthogon
clinic
test
determin
accuraci
final
establish
threshold
enabl
separ
trueposit
match
background
threshold
incorpor
metric
number
sequenc
read
align
detect
microorgan
normal
read
per
million
extern
notempl
control
sampl
intern
spikein
materi
number
nonoverlap
genom
region
cover
read
abund
clinic
sampl
rel
neg
control
sampl
avoid
report
contamin
organ
curv
roc
analysi
use
tool
determin
optim
threshold
valu
train
set
clinic
sampl
known
result
verif
preestablish
threshold
use
independ
valid
wet
lab
workflow
analysi
softwar
refer
databas
ideal
lock
valid
clinic
use
mani
laboratori
maintain
product
uptod
develop
version
clinic
refer
databas
exampl
ncbi
nucleotid
databas
updat
everi
week
product
databas
updat
regular
prespecifi
interv
standard
data
set
use
verifi
databas
updat
ensur
assay
result
accur
reproduc
error
introduc
newli
deposit
sequenc
clinic
metadata
although
substanti
cost
reduct
gener
sequenc
data
overal
persampl
reagent
cost
sequenc
remain
fairli
high
laboratori
lack
robot
equip
establish
autom
protocol
multiplex
larg
number
patient
sampl
singl
run
thu
major
librari
prepar
method
mng
perform
manual
henc
incur
consider
staff
time
addit
resourc
need
run
maintain
bioinformat
analysi
pipelin
also
consider
step
taken
ensur
regulatori
oversight
add
notabl
cost
well
lead
overal
cost
sever
hundr
thousand
dollar
per
sampl
analys
higher
mani
clinic
test
technic
improv
hardwar
need
mng
sampl
process
increas
throughput
reduc
cost
ng
procedur
becom
standard
drive
toward
increas
autom
use
liquidhandl
typic
two
biorobot
need
clinic
mng
preamplif
postamplif
step
avoid
pcr
amplicon
crosscontamin
increas
multiplex
also
possibl
greatli
enhanc
output
latest
gener
sequenc
illumina
novaseq
instrument
howev
potenti
limit
run
larger
number
sampl
per
run
longer
overal
turnaround
time
clinic
use
owe
requir
batch
process
well
sampl
workflow
comput
analysi
consider
addit
highthroughput
process
clinic
sampl
ng
may
possibl
refer
laboratori
develop
microfluid
devic
ng
sampl
librari
prepar
could
eventu
enabl
clinician
use
mng
wide
hospit
laboratori
pointofcar
set
clinic
laboratori
highli
regul
gener
laboratori
test
requir
appli
molecular
diagnost
assay
report
patient
qualiti
control
paramount
method
must
develop
ensur
analyt
accuraci
throughout
assay
workflow
import
qualiti
control
step
includ
initi
sampl
qualiti
check
librari
paramet
concentr
size
distribut
sequenc
data
gener
cluster
densiti
qscore
recoveri
intern
control
perform
extern
control
valid
data
gener
assay
develop
implement
record
made
avail
laboratori
inspector
laboratorydevelop
test
submit
regulatori
agenc
fda
usa
european
medicin
agenc
ema
europ
approv
ongo
monitor
particularli
import
mng
assay
verifi
accept
perform
time
investig
atyp
monitor
accomplish
use
sampl
intern
control
intrarun
control
sampl
swipe
test
contamin
period
profici
test
unexpect
unusu
result
investig
review
patient
clinic
chart
confirmatori
laboratori
test
use
orthogon
method
identif
microorgan
identifi
laboratori
independ
confirm
usual
clinic
refer
public
health
laboratori
test
atyp
novel
organ
assess
clinic
signific
find
report
discuss
healthcar
provid
consider
potenti
pathogen
test
treatment
option
clinic
microbi
sequenc
board
model
tumour
board
oncolog
conven
via
realtim
teleconferenc
discuss
mng
result
treatment
provid
clinic
context
fig
detect
microorgan
public
health
implic
sin
nombr
hantaviru
ebola
viru
report
appropri
relev
public
health
agenc
